[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fe4tHg0XsjyDwpt6dUoioE_t5K7w_uf6l2AhZ5UCnlNw":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":13,"question":17,"related":18,"source":22,"type":23},[],"2023-11-12 18:03:26",105323068,[8,9,10,11,12],"药物理化性质研究","药物剂型及处方筛选","药代动力学研究","生物等效性试验","药理毒理研究",{"courseId":14,"courseImg":15,"courseName":16},"ec74378bef972bb31fcc1cd3fc52e4f4","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F071f9540ec746b09fd0cdab44421f75b.jpg","药事管理与法规","下列不属于药物非临床研究的内容是",[19,24,34,44,54,64,69,79,89,99],{"answer":20,"createTime":5,"id":6,"options":21,"question":17,"source":22,"type":23},[],[8,9,10,11,12],"v1",0,{"answer":25,"createTime":26,"id":27,"options":28,"question":33,"source":22,"type":23},[],"2023-11-12 18:03:27",105323070,[29,30,31,32,11],"I期临床试验","II期临床试验","III期临床试验","IV期临床试验","根据《药品注册管理办法》,初步的临床药理学及人体安全性评价试验属于",{"answer":35,"createTime":26,"id":36,"options":37,"question":43,"source":22,"type":23},[],105323071,[38,39,40,41,42],"临床前研究申请和临床试验申请","临床试验申请和生产上市申请","生产申请和上市申请","临床前研究申请和生产上市申请","临床试验申请和再注册申请","新药申请的申报与审批,分为()两次申报与审批",{"answer":45,"createTime":26,"id":46,"options":47,"question":53,"source":22,"type":23},[],105323073,[48,49,50,51,52],"国药证字H+4位年号+4位顺序号","国药准字Z+4位年号+4位顺序号","国药证字Z+4位年号+4位顺序号","国药准字S+4位年号+4位顺序号","国药准字H+4位年号+4位顺序号","下列属于化学药品批准文号格式的是",{"answer":55,"createTime":26,"id":56,"options":57,"question":63,"source":22,"type":23},[],105323075,[58,59,60,61,62],"补充申请","仿制药品申请","进口药品申请","新药申请","再注册申请","改变、增加或取消原批准事项或内容的注册申请属于",{"answer":65,"createTime":26,"id":66,"options":67,"question":68,"source":22,"type":23},[],105323077,[61,60,59,58,62],"《化学药品注册分类改革工作方案》中指出的境外上市的药品申请在境内上市应按照《药品注册管理办法》中()程序申报",{"answer":70,"createTime":26,"id":71,"options":72,"question":78,"source":22,"type":23},[],105323078,[73,74,75,76,77],"省级药品监督管理部门","国家药品监督管理部门","药检所","药品评价中心","药品审评中心","新药临床试验审批过程中负责技术审查的部门是",{"answer":80,"createTime":26,"id":81,"options":82,"question":88,"source":22,"type":23},[],105323079,[83,84,85,86,87],"一切与医药行业有关的发明创造和智力劳动成果的财产权","与医药行业相关的发明创造","医药行业的智力劳动成果的财产权","医药信息和相关前沿保密技术","医药行业的计算机软件技术","药品知识产权是指",{"answer":90,"createTime":26,"id":91,"options":92,"question":98,"source":22,"type":23},[],105323081,[93,94,95,96,97],"病例选取≥2000例,对象要求是适应症患者,以开放试验进行","病例选取≥300组,对象要求是适应症患者,以多中心随机盲法对照临床试验进行","病例选取≥100对,对象要求是适应症患者,采取随机盲法对照等多种形式","病例选取20-30例,对象要求是健康志愿者或病人,以开放试验进行","病例选取≥200组,对象要求是适应症患者,以开放试验进行","以下哪项是Ⅱ期临床试验的试验要求",{"answer":100,"createTime":26,"id":101,"options":102,"question":108,"source":22,"type":23},[],105323082,[103,104,105,106,107],"GMP","GAP","GLP","GSP","GCP","《药品注册管理办法》规定,药品非临床研究应当执行有关管理规定,其中安全性评价研究必须执行"]